Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by MiSdyngNASTYon Jul 05, 2020 11:18pm

232 Views

Post# 31227004

SAME 💩 DIFFERENT DRUG

It is funny to me that the same pumper bagholders are saying the same things about this fake covid drug that they were saying about the GVHD one. Do I need to remind you that Kalytera is in default for that and it will be going back to David Bassa? Now they are trying the same scam on you gullible dreamers again. If KLY by some miracle starts trading again I will have lost all faith in the TSXV. Management should be behind bars and you bagholders are too blinded by desperation to see it.

<< Previous

Bullboard Posts

Next >>

Optimi Health makes commercial entry into Australia